Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Iovance Biotherapeutics Inc
F:2LB
Iovance Biotherapeutics Inc
F:2LB
Price:
13.22
EUR
7.65%
Market Closed
Market Cap:
€3.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Iovance Biotherapeutics Inc
F:2LB
|
US |
|
D&L Industries Inc
OTC:DALQF
|
PH |
|
East West Petroleum Corp
OTC:EWPMF
|
CA |
|
Helix BioPharma Corp
F:HBP0
|
CA |
|
S
|
Somnigroup International Inc
F:TPD
|
US |
|
C
|
China Merchants Port Holdings Co Ltd
F:CPM
|
HK |
|
T
|
Tractor Supply Co
F:TR4
|
US |
|
H
|
Hanil Forging Industrial
KOSDAQ:024740
|
KR |
Wall St Price Targets
2LB Price Forecast
Based on 13 analysts
Based on 13 analysts
-85% Downside
from
€13.22
today
Iovance Biotherapeutics Inc (2LB)’s 12-month stock price forecast through October 2027 has a consensus target of €2.03, implying 85% downside. The forecast is based on price targets from 13 Wall Street analysts.
2LB Analyst Rating
No ratings yet
No ratings yet
Iovance Biotherapeutics Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2LB's stock price target?
Price Target
2.03
EUR
2.03
EUR
According to Wall Street analysts, the average 1-year price target for 2LB is 2.03 EUR with a low forecast of 0.91 EUR and a high forecast of 2.7 EUR.
What is the Revenue forecast for Iovance Biotherapeutics Inc?
Projected CAGR
34%
34%
The compound annual growth rate for Revenue over the next 8 years is 34%.
What is the Gross Profit forecast for Iovance Biotherapeutics Inc?
Projected CAGR
48%
48%
The compound annual growth rate for Gross Profit over the next 8 years is 48%.